Month: June 2021

CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it has dosed the first patient in the Part B expansion phase of its Phase 1 monotherapy clinical trial of CUE-101 at the recommended Phase 2 dose of 4mg/kg. The Phase 1b portion of the CUE-101 monotherapy clinical trial in patients with HPV+ second line and beyond (2L+) head and neck squamous cell carcinoma (HNSCC) is expected to enroll up to 20 patients. The data supporting the patient expansion has been encouraging to date, with six patients having confirmed stable disease (SD) and one patient with a confirmed partial response of approximately...

QUEBEC CITY, June 10, 2021 (GLOBE NEWSWIRE) — (TSXV: HEO) – H2O Innovation Inc. (“H2O Innovation” or the “Corporation”) is pleased to announce its nomination for the Out of Quebec Outreach prize as part of the Fidéïdes 2021 of the Chamber of Commerce and Industry of Quebec. The winner will be elected during the virtual Fidéïdes Gala, on November 3rd. The Fidéïdes is a recognized and highly esteemed event in the business community of the greater Quebec City and Chaudière-Appalaches region. It rewards companies that have stood out over the past year by their exceptional business performance. The category in which the Corporation has qualified recognizes and honors those who, through their organization, their work, their involvement, their achievements, have distinguished themselves outside of Quebec and have made it possible to raise...

MiQLab detects 100% of C. acnes samples 36-times faster than a culture started from ideal laboratory conditions (in 2 hours versus 3 days) MiQLab can be as much as 168-times faster than a culture started from a bioreactor sample (2 hours versus 14 days) Adopting MiQLab could lead to significant cost savings for biopharmaceutical manufacturersBEVERLY, Mass., June 10, 2021 (GLOBE NEWSWIRE) — LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) a molecular diagnostics company that develops fully automated, rapid pathogen detection systems, today announced it has successfully utilized the MiQLab™ System to detect the presence of a slow growing bacterium, responsible for millions of dollars of damages to biopharmaceutical manufacturers. Dr. Jack Regan, LexaGene’s CEO and Founder stated, “Last fall, a global biopharmaceutical manufacturer...

Michael ShineSenior Vice President, CommercialMALVERN, Pa., June 10, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that Michael Shine will be joining Ocugen as Senior Vice President, Commercial. Michael Shine is a pharmaceutical and biotechnology executive with nearly 35 years of industry experience. Over the course of his career, Mr. Shine has held leadership positions within large pharmaceutical companies, including Novapharm Therapeutics, Colgate Oral Pharmaceutical, and Pfizer Vaccines (formerly Wyeth). He also served as Chief Marketing Officer with Thomas Reuters and spent more than eight years in the start-up...

Emerging Insights about RAS-Addicted Cancers, Drug Resistance and Treatment Strategies REDWOOD CITY, Calif., June 10, 2021 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that it will host a Science Talk webcast to highlight learnings from recent preclinical and clinical studies of RAS inhibitors. The webcast, to be held at 4:00 p.m. Eastern on June 17, 2021, will provide a perspective on emerging insights about RAS-addicted cancers, including the implications of common drug resistance mechanisms on targeted treatment strategies.   The presentation will be led by Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman, and Steve Kelsey, M.D., president, research...

AUSTIN, Texas, June 10, 2021 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company, today announced it will present a poster at the 6th Biennial Pediatric Neuro-Oncology Research Conference hosted by the Society for Neuro-Oncology (SNO), being held virtually June 10-12, 2021. The poster presentation is titled, “A two-part, Phase I study of Rhenium-186 Nanoliposomes (186RNL) delivered by convection enhanced delivery (CED) for recurrent, refractory, or progressive ependymoma and high-grade glioma (HGG).” The lead presenter is Dr. Ashley S. Plant-Fox, Attending Physician, Neuro-Oncology, Assistant Professor of Pediatrics, and A.M. Khokhar Research Scholar at the Northwestern University Feinberg School of Medicine and the Ann & Robert H. Lurie Children’s Hospital of...